Relmada Execs to Present at Leerink Healthcare Conference
Event summary
- Relmada Therapeutics execs to participate in fireside chat at Leerink Partners Global Healthcare Conference on March 10, 2026.
- CEO Sergio Traversa and CFO Maged Shenouda to present company updates.
- One-on-one investor meetings scheduled during the conference.
- Webcast available on Relmada's investor relations page.
The big picture
Relmada's participation in the Leerink Partners Global Healthcare Conference comes as the biotech sector faces increasing scrutiny over clinical trial outcomes and funding. The company's focus on oncology and central nervous system disorders positions it in a competitive but high-growth segment of the healthcare industry. Investors will be watching for updates on the progress of NDV-01 and sepranolone, both of which are in mid-stage clinical development.
What we're watching
- Clinical Progress
- How Relmada's mid-stage clinical developments for NDV-01 and sepranolone will be positioned in the presentation.
- Investor Sentiment
- Whether the fireside chat and investor meetings will shift market perception of Relmada's pipeline.
- Strategic Direction
- The pace at which Relmada plans to advance its oncology and CNS-focused therapies.
Our editorial coverage:
Related topics